Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab
NCT05002517
·
clinicaltrials.gov ↗
PHASE3
Phase
UNKNOWN
Status
60
Enrollment
OTHER
Sponsor class
Conditions
COVID-19 Pneumonia
Interventions
DRUG:
Tociliziumab group
DRUG:
Methylprednisolone group
Sponsor
Biogipuzkoa Health Research Institute